retatrutide phase 3 trial results Eli Lilly's data is in on Retatrutide! Here's what they found New GLP-3 drug significantly slashes

The BBSS began in 2015 and consisted of a battery of baseline tests established one month before the intervention and repeated at 1-, 3-, 6- and 12-month follow-up clinical visits

However, the broad distribution of GLP-1 receptors across various tissues, such as the pancreas, lungs, kidneys, central nervous system, cardiovascular system, gastrointestinal tract, skin, and thyroid gland, has raised concerns about the potential impact of GLP-1 RAs on cancer development and progression [23]

My Ivim provider took the time to understand my goals and adjusted my dose based on how my body responded, which made a huge difference

Back Phelan, M (30 May 2024) 'Winning researchers unlocked GLP-1 drugs for obesity', Science , 384/6699

Cease-and-desist letters from pharmaceutical manufacturers require immediate legal attention